MA26875A1 - Composes azapolycycliques a noyau aryle condensé - Google Patents

Composes azapolycycliques a noyau aryle condensé

Info

Publication number
MA26875A1
MA26875A1 MA26775A MA26775A MA26875A1 MA 26875 A1 MA26875 A1 MA 26875A1 MA 26775 A MA26775 A MA 26775A MA 26775 A MA26775 A MA 26775A MA 26875 A1 MA26875 A1 MA 26875A1
Authority
MA
Morocco
Prior art keywords
compounds
condensed aryl
formula
azapolycyclic
azapolycyclic compounds
Prior art date
Application number
MA26775A
Other languages
English (en)
Inventor
Wadsworth Coe Jotham
Roanne Palmer Brooks Paige
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26875A1 publication Critical patent/MA26875A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC, REVENDICATION DE PRIORITES US 25 Février 2000 09/514,002 Voir en annexe le titre de l'invention et le texte de l'abrégé Composés azapolycycliques à noyau aryle condensé L'invention concerne des composés de formule I et leurs sels pharmaceutiquement acceptables, formule dans laquelle R1, R2 et R3 répondent aux définitions figurant dans le présent mémoire ; des intermédiaires pour la synthèse de ces composés, des compositions pharmaceutiques contenant ces composés ; et des méthodes d'utilisation de ces composés dans le traitement de troubles neurologiques et psychologiques.
MA26775A 2000-02-25 2002-08-13 Composes azapolycycliques a noyau aryle condensé MA26875A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/514,002 US6605610B1 (en) 1997-12-31 2000-02-25 Aryl fused azapolycyclic compounds

Publications (1)

Publication Number Publication Date
MA26875A1 true MA26875A1 (fr) 2004-12-20

Family

ID=24045406

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26775A MA26875A1 (fr) 2000-02-25 2002-08-13 Composes azapolycycliques a noyau aryle condensé

Country Status (40)

Country Link
US (3) US6605610B1 (fr)
EP (2) EP1619192B1 (fr)
JP (1) JP2003524002A (fr)
KR (1) KR100537976B1 (fr)
CN (1) CN1263745C (fr)
AP (1) AP1860A (fr)
AT (2) ATE453643T1 (fr)
AU (2) AU784081B2 (fr)
BG (1) BG65891B1 (fr)
BR (1) BR0108610A (fr)
CA (1) CA2401229C (fr)
CR (1) CR6726A (fr)
CU (1) CU23148A3 (fr)
CY (1) CY1105301T1 (fr)
CZ (1) CZ303203B6 (fr)
DE (2) DE60120366T2 (fr)
DK (2) DK1259489T3 (fr)
DZ (1) DZ3328A1 (fr)
EA (1) EA005316B1 (fr)
EE (1) EE200200475A (fr)
ES (2) ES2336800T3 (fr)
GE (1) GEP20053454B (fr)
HK (1) HK1050894A1 (fr)
HR (1) HRP20020700A2 (fr)
HU (1) HU229482B1 (fr)
IL (2) IL150639A0 (fr)
IS (1) IS2293B (fr)
MA (1) MA26875A1 (fr)
MX (1) MXPA02008311A (fr)
NO (1) NO323608B1 (fr)
NZ (1) NZ519973A (fr)
OA (1) OA12181A (fr)
PL (1) PL365163A1 (fr)
PT (1) PT1259489E (fr)
RS (1) RS51123B (fr)
SI (1) SI1259489T1 (fr)
SK (1) SK12042002A3 (fr)
UA (1) UA74813C2 (fr)
WO (1) WO2001062736A1 (fr)
ZA (1) ZA200206768B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001840T2 (tr) * 1997-12-31 2000-12-21 Pfizer Products Inc. Arile bağlı azopolisiklik bileşikler
EP1383733B1 (fr) * 2001-04-20 2008-03-05 Pfizer Products Inc. Procede de preparation d'indenes 1,3-substitues et composes azapolycycliques d'aryle fondus
CA2460118A1 (fr) * 2001-10-31 2003-05-08 Pfizer Products Inc. Agonistes du recepteur d'acetylcholine nicotinique pour traiter les impatiences des membres inferieurs
PT1448235E (pt) * 2001-11-30 2007-05-31 Pfizer Prod Inc Composições farmacêuticas orais de libertação controlada de 5,8,14-triazatetraciclo ( 10.3.1.0(2,11).0(4,9) ) - hexadeca-2(11),3,5,7,9-pentaeno.
AU2002365314A1 (en) * 2001-11-30 2003-06-10 Pfizer Products Inc. Aryl fused azapolycyclic compounds
BR0312297A (pt) 2002-07-18 2005-04-12 Cytos Biotechnology Ag Conjugados veìculos de hapteno e seu uso
WO2004037850A2 (fr) * 2002-10-22 2004-05-06 Millipore Corporation Formation par immersion de structures composites dans des plaques multi-puits et procede associe
RU2284319C2 (ru) * 2002-11-25 2006-09-27 Пфайзер Продактс Инк. Усовершенствованный способ получения 1,3-замещенных инденов
MXPA05007565A (es) * 2003-01-15 2005-09-21 Pfizer Prod Inc Procedimiento mejorado de preparacion de lactamas policiclicas fusionadas con arilos.
BRPI0410219A (pt) * 2003-05-20 2006-05-09 Pfizer Prod Inc composições farmacêuticas de vareniclina
PL378491A1 (pl) * 2003-06-04 2006-05-02 Pfizer Products Inc. Sposób wytwarzania podstawionych chinoksalin z dianiliny i z 2,3-dihydroksy-1,4-dioksanu
WO2005007630A2 (fr) * 2003-07-21 2005-01-27 Pfizer Products Inc. Composes azapolycycliques fusionnes avec aryle
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
JP4308263B2 (ja) 2003-10-14 2009-08-05 ゼノポート，インコーポレイティド γ−アミノ酪酸アナログの結晶形
JP2007516275A (ja) * 2003-12-23 2007-06-21 ファイザー・プロダクツ・インク 認知増強および精神病性障害のための治療的組合せ
WO2006006071A1 (fr) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution de compose azapolycyclique fusionne aryle
EP1866308B1 (fr) * 2005-02-24 2008-10-22 Pfizer Products Incorporated Preparation d'une quinoxaline substituee de haute purete
RU2403016C2 (ru) * 2006-04-24 2010-11-10 Пфайзер Продактс Инк. Асимметричные мембраны для устройств доставки лекарственного препарата
WO2008060487A2 (fr) * 2006-11-09 2008-05-22 Pfizer Products Inc. Polymorphes d'intermédiaires nicotiniques
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009034431A2 (fr) 2007-09-10 2009-03-19 Pfizer Inc. Formes posologiques à libération contrôlée de la varenicline
WO2009065872A2 (fr) * 2007-11-20 2009-05-28 Medichem, S.A. Procédés améliorés pour la synthèse de l-tartrate de varénicline
US8703774B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
CN101952276B (zh) * 2007-12-07 2014-10-22 Abbvie德国有限责任两合公司 5-卤素取代的羟吲哚衍生物和其用于治疗加压素依赖性疾病的用途
JP5645217B2 (ja) 2007-12-07 2014-12-24 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー ５，６−二置換オキシンドール誘導体およびバソプレッシン依存性疾患を治療するためのこれらの使用
JP5701607B2 (ja) * 2007-12-07 2015-04-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
JP2011516489A (ja) 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
EP2268639A2 (fr) * 2008-05-22 2011-01-05 Teva Pharmaceutical Industries Ltd. Tosylate de varénicline, un intermédiaire dans le procédé de préparation du l-tartrate de varénicline
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (fr) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Procédés de purification du sel l-tartrate de varénicline et préparation de formes cristallines du sel l-tartrate de varénicline
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
KR20110132564A (ko) 2009-02-11 2011-12-08 선오비온 파마슈티컬스 인코포레이티드 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
WO2010151524A1 (fr) * 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Formes solides des sels de varénicline et leurs procédés de préparation
CN110381919A (zh) 2017-03-03 2019-10-25 西梯茜生命工学股份有限公司 含有伐尼克兰或其药学上可接受的盐的包合复合物的口服施用制剂
JP2023509453A (ja) * 2020-01-03 2023-03-08 ブルー オーク ファーマシューティカルズ インコーポレイテッド Ｃｎｓ障害を処置するための化合物および組成物
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
TR200001840T2 (tr) * 1997-12-31 2000-12-21 Pfizer Products Inc. Arile bağlı azopolisiklik bileşikler
EP0955301A3 (fr) 1998-04-27 2001-04-18 Pfizer Products Inc. Dérivés de 7-aza-bicyclo[2.2.1]-heptane, leur préparation et utilisation sur la base d'affinité pour les recepteurs de l'acetylcholine nicotinique neuronaux
EA003669B1 (ru) 1998-04-29 2003-08-28 Пфайзер Продактс Инк. Конденсированные с арилом азаполициклические соединения
CA2361525C (fr) * 1999-01-29 2009-12-08 Abbott Laboratories Derives diazabicycliques utiles en tant que ligands du recepteur nicotinique de l'acetylcholine
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
EP1372692A4 (fr) * 2001-03-19 2005-10-26 Sloan Kettering Inst Cancer Synthese asymetrique de (s,s,r)-(-)-actinonine, de ses analogues et ses utilisations
WO2005007630A2 (fr) * 2003-07-21 2005-01-27 Pfizer Products Inc. Composes azapolycycliques fusionnes avec aryle
US8123947B2 (en) 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis

Also Published As

Publication number Publication date
CA2401229C (fr) 2007-10-02
NO20024042L (no) 2002-10-17
NZ519973A (en) 2004-04-30
YU59602A (sh) 2005-06-10
EP1259489A1 (fr) 2002-11-27
EP1619192A2 (fr) 2006-01-25
RS51123B (sr) 2010-10-31
WO2001062736A1 (fr) 2001-08-30
CA2401229A1 (fr) 2001-08-30
ATE328872T1 (de) 2006-06-15
SI1259489T1 (sl) 2006-10-31
BG106908A (bg) 2003-04-30
JP2003524002A (ja) 2003-08-12
DE60140965D1 (de) 2010-02-11
DE60120366D1 (de) 2006-07-20
CY1105301T1 (el) 2010-03-03
ATE453643T1 (de) 2010-01-15
EP1619192A3 (fr) 2006-03-22
US7205300B2 (en) 2007-04-17
SK12042002A3 (sk) 2004-02-03
EA200200716A1 (ru) 2003-02-27
CN1263745C (zh) 2006-07-12
US20030130261A1 (en) 2003-07-10
CZ303203B6 (cs) 2012-05-23
IS2293B (is) 2007-10-15
HUP0204580A2 (hu) 2003-04-28
IL150639A (en) 2011-10-31
CN1406227A (zh) 2003-03-26
CZ20022778A3 (cs) 2003-09-17
AU2874801A (en) 2001-09-03
AU2005234671B2 (en) 2008-04-17
US7144882B2 (en) 2006-12-05
CR6726A (es) 2003-10-28
CU23148A3 (es) 2006-06-29
DE60120366T2 (de) 2007-07-05
KR100537976B1 (ko) 2005-12-21
NO323608B1 (no) 2007-06-18
OA12181A (en) 2006-05-09
NO20024042D0 (no) 2002-08-23
HU229482B1 (en) 2014-01-28
AP2002002604A0 (en) 2002-09-30
DK1619192T3 (da) 2010-03-29
EA005316B1 (ru) 2004-12-30
ES2263640T3 (es) 2006-12-16
AU784081B2 (en) 2006-02-02
PT1259489E (pt) 2006-08-31
HRP20020700A2 (en) 2004-12-31
US20030130260A1 (en) 2003-07-10
UA74813C2 (en) 2006-02-15
MXPA02008311A (es) 2002-12-09
IL150639A0 (en) 2003-02-12
ZA200206768B (en) 2003-09-23
DK1259489T3 (da) 2006-10-09
BG65891B1 (bg) 2010-04-30
US6605610B1 (en) 2003-08-12
ES2336800T3 (es) 2010-04-16
AP1860A (en) 2008-07-02
HK1050894A1 (en) 2003-07-11
GEP20053454B (en) 2005-02-25
KR20030005209A (ko) 2003-01-17
IS6459A (is) 2002-07-05
AU2005234671A1 (en) 2005-12-15
HUP0204580A3 (en) 2005-04-28
PL365163A1 (en) 2004-12-27
EP1259489B1 (fr) 2006-06-07
EE200200475A (et) 2003-12-15
BR0108610A (pt) 2002-11-19
EP1619192B1 (fr) 2009-12-30
DZ3328A1 (fr) 2001-08-30

Similar Documents

Publication Publication Date Title
MA26875A1 (fr) Composes azapolycycliques a noyau aryle condensé
MA27596A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA27439A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
TN2009000471A1 (fr) Composes amino-heterocycliques
TNSN98237A1 (fr) Composes azapolycycliques a noyau aryle condense, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26689A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27138A1 (fr) Composes heteroaryliques condenses a substituant azabicyclique pour le traitement d'une maladie
MA27451A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
TNSN04137A1 (fr) Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
MA31800B1 (fr) Dérivés de tétrahydroquinoléine pour traiter des troubles de stress post-traumatique
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
MA26864A1 (fr) Antagonistes du facteur de liberation de corticotrophine.
TNSN06200A1 (fr) Derives de quinoleine nouveaux
TNSN97044A1 (fr) Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.
MA27716A1 (fr) 4-aminopyrimidine-5-one
TNSN07366A1 (fr) Tetrahydro-pyridoazepine -8- ones et composes apparentes, pour le traitement de la schizophrenie
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
MA26690A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1,2-a ] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
TNSN98151A1 (fr) Derives de 2 - (4 - aryl - ou heteroaryl - piperazine - 1 - ylmethyl) -1 h - indole.
MA27197A1 (fr) Sels de tolterodine
FR2716883B1 (fr) Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
TNSN05074A1 (fr) Piperazines heterocycliques substituees pour le traitement de la schizophrenie
EP0879054B1 (fr) Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues
MA27167A1 (fr) ACIDES 3-(IMIDAZOLYL)-2-ALKOXYPROPANOiQUES SERVANT D'INHIBITEURS DE TAFIa.